公开(公告)号：US20250129377A1

公开(公告)日：2025-04-24

申请号：US18746423

申请日：2024-06-18

Applicant: Cellectis

Inventor： Nicholas Baltes ,  Javier Gil Humanes

IPC: C12N15/82 ,  C12N9/16

Abstract: Materials and methods are provided for making plants (e.g., Triticum varieties) with increased levels of dietary fiber, such as by making TALE nuclease-induced mutations in alleles encoding starch branching enzyme IIa (SBEIIa) and starch branching enzyme IIb (SBEIIb).

公开(公告)号：US12133867B2

公开(公告)日：2024-11-05

申请号：US18393322

申请日：2023-12-21

Applicant: CELLECTIS SA

Inventor： Julianne Smith ,  Phillippe Duchateau ,  Murielle Derrien

IPC: A61K35/17 ,  A61K31/365 ,  A61K39/395 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28

Abstract: The present invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US20240360196A1

公开(公告)日：2024-10-31

申请号：US18607387

申请日：2024-03-15

Applicant: ALLOGENE THERAPEUTICS, INC. ,  CELLECTIS

Inventor： Arvind RAJPAL ,  Shobha Chowdary POTLURI ,  Laurent POIROT ,  Alexandre JUILLERAT ,  Thomas Charles PERTEL ,  Donna Marie STONE ,  Barbra Johnson SASU

IPC: C07K14/705 ,  A61K35/17 ,  A61K39/00 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783

CPC classification number: C07K14/70503 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/3069 ,  C12N5/0636 ,  A61K2039/5156 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/03 ,  C07K2319/70 ,  C07K2319/74 ,  C12N2510/00

Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising



an extracellular domain comprising an antigen binding domain,
a transmembrane domain and,
an intracellular domain
wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein
X1 is an amino acid
X2 is an amino acid
X3 is an amino acid and
X4 is V or I.

公开(公告)号：US20240309397A1

公开(公告)日：2024-09-19

申请号：US18530878

申请日：2023-12-06

Applicant: Cellectis

Inventor： Roman GALETTO ,  Agnes GOUBLE ,  Stephanie GROSSE ,  Cecile MANNIOUI ,  Laurent POIROT ,  Andrew SCHARENBERG ,  Julianne SMITH

IPC: C12N15/85 ,  A61K35/17 ,  A61K38/00 ,  A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

CPC classification number: C12N15/85 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C12N5/0636 ,  A61K38/00 ,  A61K39/00 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/74 ,  C12N2501/39 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00

Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppresive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular, TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection. of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US20240269178A1

公开(公告)日：2024-08-15

申请号：US18451816

申请日：2023-08-17

Applicant: Cellectis

Inventor： Roman Ariel GALETTO ,  Julianne SMITH ,  Andrew SCHARENBERG ,  Cécile SCHIFFER-MANNIOUI

IPC: A61K35/17 ,  A61K38/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

CPC classification number: A61K35/17 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C12N5/0636 ,  A61K38/00 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/74 ,  C12N2501/39 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00

Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Recept—or in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.

公开(公告)号：US12012607B2

公开(公告)日：2024-06-18

申请号：US17052351

申请日：2019-05-02

Applicant: CELLECTIS

Inventor： Nicholas Baltes ,  Javier Gil Humanes

IPC: C12N15/82 ,  C12N9/16

CPC classification number: C12N15/8245 ,  C12N9/16 ,  C12N15/8262

Abstract: Materials and methods are provided for making plants (e.g., Triticum varieties) with increased levels of dietary fiber, such as by making TALE nuclease-induced mutations in alleles encoding starch branching enzyme IIa (SBEIIa) and starch branching enzyme IIb (SBEIIb).

公开(公告)号：US20240141293A1

公开(公告)日：2024-05-02

申请号：US18540309

申请日：2023-12-14

Applicant: CELLECTIS

Inventor： Brian BUSSER ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Laurent POIROT ,  Julien VALTON

IPC: C12N5/0783 ,  A61K35/17 ,  C12N9/22 ,  C12N15/90

CPC classification number: C12N5/0638 ,  A61K35/17 ,  C12N9/22 ,  C12N15/907 ,  C12N2510/00 ,  C12N2750/14143 ,  C12N2830/008

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

公开(公告)号：US20230287454A1

公开(公告)日：2023-09-14

申请号：US18303080

申请日：2023-04-19

Applicant: CELLECTIS

Inventor： Jean-Pierre CABANIOLS ,  Jean-Charles EPINAT ,  Philippe DUCHATEAU

IPC: C12N15/86 ,  C12N5/0783 ,  C12N9/22 ,  C12N13/00 ,  C12N15/113 ,  C12N15/90

CPC classification number: C12N15/86 ,  C12N5/0636 ,  C12N9/22 ,  C12N13/00 ,  C12N15/113 ,  C12N15/902 ,  C12N2310/20 ,  C12N2510/00 ,  C12N2800/80

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.

公开(公告)号：US11692169B2

公开(公告)日：2023-07-04

申请号：US16939466

申请日：2020-07-27

Applicant: Cellectis

Inventor： Philippe Duchateau ,  Laurent Poirot

IPC: C12N5/0783 ,  A61K35/17 ,  A61P35/02 ,  A61P35/00

CPC classification number: C12N5/0636 ,  A61K35/17 ,  A61P35/00 ,  A61P35/02 ,  C12N2501/599 ,  C12N2510/00 ,  Y02A50/30

Abstract: Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CS1 or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.

公开(公告)号：US20230138915A1

公开(公告)日：2023-05-04

申请号：US16340412

申请日：2017-10-19

Applicant: CELLECTIS

Inventor： Philippe DUCHATEAU ,  Brian BUSSER ,  Alexandre JUILLERAT ,  Anne-Sophie GAUTRON ,  Laurent POIROT

IPC: C12N15/90 ,  C12N15/11 ,  C12N9/22 ,  C12N5/0783 ,  C07K14/725

Abstract: The invention relates to the fields of immunotherapy, molecular biology and recombinant nucleic acid technology. In particular, the invention relates to a TALEN-modified human primary cell comprising in its genome, a modified human T cell receptor alpha gene with an insertion comprising at least, from 5′ to 3′, a polynucleotide encoding a self-cleaving peptide, a chimeric antigen receptor, wherein the cell has undetectable cell-surface expression of the endogenous alpha beta T cell receptor as compared to a TCR positive control cell and expresses a receptor to target a pathological cell, use of said cell for treating a disease, including cancer. The invention further relates to methods for producing such a TALEN-modified cell, and to means for detecting such an engineered human primary cell or other genetically modified human primary cell obtained using alternative and/or additional rare cutting endonucleases.